IPSC News and Press, Century Therapeutics Inc. From 09/14/23

2023-09-14 10:00:06 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-09-01 20:00:14 ET Summary CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf cell therapies. B...

2023-08-28 17:11:39 ET JP Morgan has downgraded Century Therapeutics ( NASDAQ: IPSC ) to neutral, commenting that it sees the stock as range-bound over the near-to-mid-term as investors wait for proof-of-concept data for its lead drug candidate CNTY-101 in the treatment of B-cell ly...

2023-08-09 12:25:54 ET Century Therapeutics press release ( NASDAQ: IPSC ): Q2 GAAP EPS of -$0.56. Revenue of $0.09M. For further details see: Century Therapeutics GAAP EPS of -$0.56, revenue of $0.09M

– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended second quarter 2023 with cash, cash equivalents, and investments of $301.0...

2023-07-06 17:26:36 ET Gainers: Century Therapeutics ( NASDAQ: IPSC ) +8% . Codexis ( CDXS ) +5% . Alignment Healthcare ( ALHC ) +4% . Wag! Group  ( PET ) +4% . Cadiz ( CDZI ) +3% . Losers: Renalytix  ( RN...

2023-05-11 09:56:04 ET Century Therapeutics press release ( NASDAQ: IPSC ): Q1 GAAP EPS of -$0.53. Revenue of $1.72M (+63.8% Y/Y). For further details see: Century Therapeutics GAAP EPS of -$0.53, revenue of $1.72M

– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting – – Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive ...

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., ad-interim Chief Execu...

2023-04-12 09:58:06 ET Century Therapeutics ( NASDAQ: IPSC ) said its Chief Executive Officer Lalo Flores had stepped down as Chief Executive Officer and as a member of the Board of Directors to pursue other opportunities. The company said it had appointed Chief Tech...